Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Eli Lilly announced positive 48-week Phase 2b results for EloraTZP, its combination of the amylin agonist eloralintide and tirzepatide, in 367 adults with obesity or overweight and type 2 diabetes. The best-performing combination produced average weight loss of 54.1 lbs (23.3%) and A1C reduction of 2.9%, versus 34.4 lbs (14.8%) and 2.4% for tirzepatide 15 mg alone.
Key figures
- Drug Name
- EloraTZP (eloralintide + tirzepatide)
- Phase Of Trial
- Phase 2b
- Participants
- 367
- Weight loss best
- 54.1 lbs (23.3%)
- A1c reduction best
- 2.9%
- Trial duration weeks
- 48
- Weight loss tirzepatide 15mg
- 34.4 lbs (14.8%)
- A1c reduction tirzepatide 15mg
- 2.4%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.